Bristol-Myers Squibb (NYSE:BMY) recently announced positive topline results from its Phase 3 trials for Sotyktu, generating ...

Shares of Bristol Myers Squibb Co. BMY advanced 1.90% to $60.02 Friday, on what proved to be an all-around dismal trading ...

We recently published a list of 10 Firms End Friday Strong; 3 Reach All-Time Highs. In this article, we are going to take a ...

Bristol-Myers Squibb awarded its CEO nearly $19 million in compensation for 2024, following a challenging year for the ...

BMY has enjoyed robust capital appreciation over the past few months, significantly aided by the ongoing market rotation to ...

The SEC has rebuffed a Bristol-Myers Squibb Co. campaign against a shareholder proposal urging it to scrap its diversity, ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

This was the stock's second consecutive day of losses.

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology ...

BMS says it is combining AI and machine learning with its researchers’ expertise in drug targets and mechanisms of action, to ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...